Alpha 2.0
Login Register
» Articles » PMID: 12235060

Hepatocellular Carcinoma: is Current Therapy Really Altering Outcome?

Overview
Journal Gut
Specialty Gastroenterology
Date 2002 Sep 18
PMID 12235060
Citations 27
Authors
P J Johnson
Affiliations
Soon will be listed here.
Abstract

Progress in the management of hepatocellular carcinoma (HCC) has been slow and has limited impact on outcome. Most patients with HCC have two diseases--chronic liver disease and HCC--and complex interactions between the two have major implications for diagnosis and prognosis as well as the management of HCC. The disease is most prevalent in those areas of the world where the infrastructure for clinical trials is least developed. Also, the aetiology of the disease varies around the world and it is still not known whether HCCs of different aetiologies have different prognoses. Current treatment is making an impact on the management of HCC but further progress awaits not only the development of more effective treatments but also the development of adequate methodologies to assess the impact of these treatments.

Citing Articles

Cell membrane breakage and triggering T cell infiltration are involved in human telomerase reverse transcriptase (hTERT) promoter-driven novel peptide KK-64 for liver cancer gene therapy.

Lu Y, Ma J, Lin J, Tian Y, Ma Y, Wang W Bioengineered. 2021; 12(2):12708-12721.

PMID: 34898368 PMC: 8809941. DOI: 10.1080/21655979.2021.2010314.

Phytochemical evaluation and anticancer activity of rambutan ( fruit endocarp extracts against human hepatocellular carcinoma (HepG-2) cells.

Perumal A, Alsalhi M, Kanakarajan S, Devanesan S, Selvaraj R, Tamizhazhagan V Saudi J Biol Sci. 2021; 28(3):1816-1825.

PMID: 33732067 PMC: 7938207. DOI: 10.1016/j.sjbs.2020.12.027.

The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W Cell Death Discov. 2020; 6:53.

PMID: 32595984 PMC: 7305227. DOI: 10.1038/s41420-020-0287-y.

Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis.

Li J, Liu X, Cui H, Xie X Mol Clin Oncol. 2019; 12(1):15-22.

PMID: 31814972 PMC: 6888042. DOI: 10.3892/mco.2019.1941.

18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma.

Liao X, Wei J, Li Y, Zhong J, Liu Z, Liao S Medicine (Baltimore). 2018; 97(34):e11970.

PMID: 30142825 PMC: 6112887. DOI: 10.1097/MD.0000000000011970.

References
1.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View
2.
Lai E, Fan S, Lo C, Chu K, Liu C, Wong J . Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995; 221(3):291-8. PMC: 1234572. DOI: 10.1097/00000658-199503000-00012. View
3.
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki K . Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996; 334(24):1561-7. DOI: 10.1056/NEJM199606133342402. View
4.
Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan J . Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996; 111(4):1018-22. DOI: 10.1016/s0016-5085(96)70070-7. View
5.
Crews K, Kuhn J, McCarty T, Fisher T, Goldstein R, Preskitt J . Cryosurgical ablation of hepatic tumors. Am J Surg. 1997; 174(6):614-7; discussion 617-8. DOI: 10.1016/s0002-9610(97)00179-7. View